Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,467 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Withdrawn Not applicable Interventional

Dynamic Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease

NCT03324308
View directory record Official record
Conditions
Coronary Artery Disease, Ischemia
Interventions
Computed Tomography Angiography
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

NCT06066515
View directory record Official record
Conditions
Obesity
Interventions
survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Spring Valley, California • Walnut Creek, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents

NCT00258479
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
ModafinilNicotine Replacement Therapy, Modafinil
Drug
Lead sponsor
Catherine Martin, MD
Other
Eligibility
16 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 23, 2026, 10:43 AM EDT
Recruiting Phase 3 Interventional

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988
View directory record Official record
Conditions
Interstitial Lung Diseases
Interventions
Nerandomilast, Placebo matching nerandomilast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

NCT02120781
View directory record Official record
Conditions
Dysphonia Resulting From Vocal Fold Scarring, Age-related Dysphonia
Interventions
Azficel-T (autologous fibroblasts), Placebo
Biological · Drug
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 23, 2026, 10:43 AM EDT
Active, not recruiting Not applicable Interventional

Transitioning Together Boston

NCT05599711
View directory record Official record
Conditions
Autism or Autistic Traits, Family Relations
Interventions
Transitioning Together (TT) / Juntos en la Transicion (JET), Usual autism transition care
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
14 Years to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using Physical Tracking to Predict Sunburn

NCT04977700
View directory record Official record
Conditions
Prevention
Interventions
Intervention Group
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Golden, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 2 Interventional

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

NCT00258635
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
RagweedMATAMPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Novi, Michigan • Minneapolis, Minnesota • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 23, 2026, 10:43 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Pilot Testing Suicide Risk Prediction Algorithms in Primary Care

NCT07068685
View directory record Official record
Conditions
Suicide Prevention, Suicide Risk | Patient
Interventions
Suicide risk prediction algorithm
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000

NCT02765555
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 42 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.

NCT00448747
View directory record Official record
Conditions
Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Interventions
AEZS-130 (formerly ARD-07), L-ARG+GHRH
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
13
States / cities
Tempe, Arizona • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 23, 2026, 10:43 AM EDT
Recruiting Phase 3 Interventional

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

NCT07201922
View directory record Official record
Conditions
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Interventions
Nerandomilast, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

NCT05085977
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 23, 2026, 10:43 AM EDT
Recruiting Not applicable Interventional

Flo Digital Contraceptive Study

NCT07630064
View directory record Official record
Conditions
Contraception Use
Interventions
Flo Digital Contraceptive
Device
Lead sponsor
Flo Health Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Not applicable Interventional Results available

Transspinal Stimulation Plus Locomotor Training for SCI

NCT04807764
View directory record Official record
Conditions
Spinal Cord Injuries, Paraplegia, Spinal, Tetraplegia/Tetraparesis, Paraplegia, Spastic
Interventions
Standing transspinal stimulation followed by robotic gait training, Lying transspinal stimulation followed by robotic gait training, Standing sham transspinal stimulation followed by robotic gait training
Combination Product · Other
Lead sponsor
City University of New York
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Staten Island, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Withdrawn Not applicable Interventional

TREAT Foot Drop After Stroke With Ankle Robot

NCT04137809
View directory record Official record
Conditions
Foot Drop, Stroke, Hemiparesis
Interventions
AMBLE
Device
Lead sponsor
NextStep Robotics Inc.
Industry
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Not applicable Interventional

A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.

NCT05995873
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Sham unilateral transcranial photobiomodulation, transcranial photobiomodulation at 810 nm at 250 mW/cm2 for 4 minutes
Other · Device
Lead sponsor
MindLight, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newton Highlands, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

NCT05176873
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
DZD8586, Placebo
Drug
Lead sponsor
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 23, 2026, 10:43 AM EDT
Recruiting Phase 4 Interventional

Randomized Trial of SGLT2i in Heart Transplant Recipients

NCT06625073
View directory record Official record
Conditions
Heart Transplant, Cardiovascular Disease, Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Palo Alto, California • Nashville, Tennessee • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Recruiting Not applicable Interventional

Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).

NCT07660354
View directory record Official record
Conditions
Lice; Head Lice
Interventions
Medical Device (X92001483)
Device
Lead sponsor
Oystershell NV
Industry
Eligibility
1 Year and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Recruiting Phase 3 Interventional

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

NCT04715646
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
1 Month and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Hawthorne, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

NCT03564691
View directory record Official record
Conditions
Neoplasms
Interventions
MK-4830, Pembrolizumab, Carboplatin, Pemetrexed, Lenvatinib, Paclitaxel, Cisplatin, MK-4830A
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 23, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

NCT02962960
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 23, 2026, 10:43 AM EDT